Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe
about
Discovery and Development of NVB302, a Semisynthetic Antibiotic for Treatment of Clostridium difficile InfectionFecal transplantation for recurrent or refractory Clostridium difficile diarrheaThe Regulatory Networks That Control Clostridium difficile Toxin SynthesisClostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal EffectsWSES guidelines for management of Clostridium difficile infection in surgical patientsClostridium difficile infection: molecular pathogenesis and novel therapeuticsA Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management.The structure of Clostridium difficile toxin A glucosyltransferase domain bound to Mn2+ and UDP provides insights into glucosyltransferase activity and product releaseHuman mini-guts: new insights into intestinal physiology and host-pathogen interactionsPredictors of Clostridium difficile colitis infections in hospitalsVariations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficileIdentification of a Novel Lipoprotein Regulator of Clostridium difficile Spore GerminationClostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventionsSuccessful treatments with polymyxin B hemoperfusion and recombinant human thrombomodulin for fulminant Clostridium difficile-associated colitis with septic shock and disseminated intravascular coagulation: a case reportRepression of Clostridium difficile toxin gene expression by CodY.C. difficile 630Δerm Spo0A regulates sporulation, but does not contribute to toxin production, by direct high-affinity binding to target DNAComplete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital.Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005.The challenges posed by reemerging Clostridium difficile infection.Clinical and molecular characteristics of an outbreak caused by the pandemic (BI/NAP1/027) Clostridium difficile clone in a single center in Israel.Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortalitySystems analysis of the transcriptional response of human ileocecal epithelial cells to Clostridium difficile toxins and effects on cell cycle control.How do hospital professionals involved in a randomised controlled trial perceive the value of genotyping vs. PCR-ribotyping for control of hospital acquired C. difficile infections?Use of data envelopment analysis to quantify opportunities for antibacterial targets for reduction of health care-associated Clostridium difficile infection.Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.Aerial dissemination of Clostridium difficile spores.Clinical severity of Clostridium difficile PCR ribotype 027: a case-case studyTruncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin AUse of International Classification of Diseases, Ninth Revision, Clinical Modification codes and medication use data to identify nosocomial Clostridium difficile infection.The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact.Functional genomics reveals that Clostridium difficile Spo0A coordinates sporulation, virulence and metabolismDetection of Clostridium difficile infection clusters, using the temporal scan statistic, in a community hospital in southern Ontario, Canada, 2006-2011Clostridium difficile infection in older adultsAnalysis of ultra low genome conservation in Clostridium difficile.Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.Clinical Clostridium difficile: clonality and pathogenicity locus diversity.Clostridium difficile and methicillin-resistant Staphylococcus aureus shedding by slaughter-age pigs.The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives.Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom.Epidemiology of Clostridium difficile infection
P2860
Q22337439-00E11F33-6A88-4EAD-BB6F-F5F1E488C198Q24234630-902C9315-73EB-456E-B691-0C47CEF33764Q26748946-DBDE53B5-5D0D-4E9B-B0B1-E62291B880ACQ26751477-B5F6471B-7DDB-423E-9B25-248937C23D39Q26795429-BD537EE5-E407-4D5F-BF98-0A87AE8A7C29Q26864237-B1D3E931-45D4-44BF-A664-096FCA25DE72Q27335693-79BC60CF-28C5-4F0E-AE1F-F2889E36DEE8Q27681638-7D2DAC9F-A058-4F12-888E-E450454C93B8Q28066574-A106A3D2-2C42-4F66-9DD9-E176C5CCE8D6Q28395557-324322BA-0C80-4A0B-AC52-2DE8F4D416BAQ28475218-4E9FF733-56F3-4D8E-874F-CA42A323E4C1Q28550467-8156FCAD-252D-43AA-A81E-FAC8E2F29C39Q28743438-CDC1A5C2-6863-43AE-81E3-B7EEEF68ACCAQ28828482-0F74C4D1-DD0B-4661-8829-9107B4E5E79EQ29346638-4F4EDE04-A0E1-46AC-82F3-3B886C02A243Q29346639-337298DB-7BD4-493A-8A93-6AC2CD519ADAQ30228253-9CD05571-E961-4356-9363-E6ECAB73A28AQ30229124-C7A8A6B1-AE63-4AE6-97E3-6DF412924748Q30229530-FF996367-5AC7-489B-B033-3301D5C360FCQ30366574-8D9BAF6B-7B19-49F4-887B-01EDE856B00EQ30413111-273FC926-2534-4914-A8AF-3F3E01F28B73Q30428655-28D1389C-E045-429F-B5F2-02234C8395F7Q30576873-00F912FE-FEEB-475C-93AE-1EE694E90FA5Q30666603-BAC17489-A6F6-463E-8F8E-78398113D4CDQ33276804-21FD7538-62B5-44F9-A7B4-26FA39669BAEQ33316379-C9283FFC-FDB0-4F14-A1AC-17AE84F4D130Q33324391-45FE2367-B44D-4637-960A-4661A056BD50Q33475206-6C11AEF2-BA52-4A3F-B9CE-BB14E5D4496AQ33508665-9134D28D-1404-415B-A377-38B0A1F164B1Q33626443-A93469BE-65C3-4A1B-936E-D5BF528F5B1FQ33641301-080EF437-0191-4529-9218-FF45BA1A6B2EQ33646483-0FDC20BB-60F4-427F-83A5-CEA81CC5CF1CQ33771594-76B29C05-58B3-48D2-BC1E-0778AF814832Q33775602-8385734C-23D0-4A96-9BF4-E6ED8C260C60Q33782277-29BBFB68-F272-418E-B9C4-0898688A8476Q33916437-20C72D06-4ACE-4A9D-9B72-43F6967136DEQ33972040-1C433A8B-64F7-4ED1-B587-AA58BC59DD40Q34006236-DED7D789-75EB-4854-A3B2-D0A57EA6485BQ34008750-3F3321AF-59CA-487C-9E81-E6BD879A1A85Q34027474-CD9259F9-2553-4F7C-93FD-53A13B1A2EFB
P2860
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe
description
article publié dans la revue scientifique The Lancet
@fr
im September 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2005
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Toxin production by an emergin ...... se in North America and Europe
@en
Toxin production by an emergin ...... se in North America and Europe
@nl
type
label
Toxin production by an emergin ...... se in North America and Europe
@en
Toxin production by an emergin ...... se in North America and Europe
@nl
prefLabel
Toxin production by an emergin ...... se in North America and Europe
@en
Toxin production by an emergin ...... se in North America and Europe
@nl
P2093
P1433
P1476
Toxin production by an emergin ...... se in North America and Europe
@en
P2093
Angela Thompson
George Killgore
Jacques Pepin
Jon Brazier
L Clifford McDonald
Michel Warny
P304
P356
10.1016/S0140-6736(05)67420-X
P407
P50
P577
2005-09-01T00:00:00Z